ICER opens nominations for new members of its voting panels

2 December 2020 - Independent panel members debate the evidence on the effectiveness and value of new drugs and other ...

Read more →

ICER releases draft evidence report on therapies for anaemia in chronic kidney disease

30 November 2020 - Public comment period now open until 5 January 2021; requests to make oral comment during public meeting ...

Read more →

ICER Analytics launched to accelerate the real world application of ICER reports, helping payers, the life science industry, and health care policy makers move from insight to action

30 November 2020 - The Institute for Clinical and Economic Review today formally launched ICER Analytics, a new cloud-based platform that ...

Read more →

ICER publishes final report and policy recommendations for haemophilia A therapies

20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...

Read more →

Consideration of value-based pricing for treatments and vaccines is important, even in the COVID-19 pandemic

19 November 2020 - Prices send signals about consumer preferences and thus stimulate producers to make more of what people want. ...

Read more →

ICER releases draft evidence report on treatments for high cholesterol

12 November 2020 - Public comment period on preliminary draft now open until 11 December 2020; requests to make oral comment ...

Read more →

ICER provides second update to pricing models for remdesivir as a treatment for COVID-19

10 November 2020 - Based on an analysis of four studies evaluating remdesivir’s influence on mortality, ICER has concluded that the ...

Read more →

A health opportunity cost threshold for cost effectiveness analysis in the United State

3 November 2020 - Cost effectiveness analysis is an important tool for informing treatment coverage and pricing decisions, yet no consensus ...

Read more →

ICER publishes evidence report on new therapies for bladder cancer

6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care ...

Read more →

ICER publishes evidence report on digital therapeutics for opioid use disorder

6 November 2020 - The available evidence on the benefits of reSET-O, Connections, and DynamiCare has substantial limitations and can ...

Read more →

ICER Names Leigh Purvis to Governance Board, Mark McClellan to Advisory Board

2 November 2020 - New members’ broad leadership experience — spanning biomedical policymaking and consumer advocacy for ageing populations — will ...

Read more →

ICER posts draft scoping document for the assessment of Alzheimer’s disease

21 October 2020 - Document open to public comment until 10 November 2020. ...

Read more →

Biden looks to Germany for answers on how to tackle high U.S. drug prices

20 October 2020 - With the U.S. election just two weeks away, Democratic presidential nominee Joe Biden is offering clues ...

Read more →

ICER publishes final report and policy recommendations for targeted immune modulator therapies for ulcerative colitis

16 October 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of vedolizumab over adalimumab. ...

Read more →

ICER publishes evidence report on therapies for haemophilia A

16 October 2020 - Emicizumab assessed as providing comparable or better clinical benefits when compared to common current dosing levels of ...

Read more →